A Phase 2 interventional study of Ranolazine and Dronedarone in Atrial Fibrillation, sponsored by Gilead Sciences. Completed at 50 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.
Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 16th largest by enrollment, is the only one that started in 2012, is one of 2 in phase 2, and was the 17th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:
Shanghai East Hospital · Sites in China
Ages 18–80
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 11
First in 2001; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is below the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 164 across the 26 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing dronedarone in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of ranolazine and of low-dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment. AFB is defined as the total time a participant is in atrial tachycardia/atrial fibrillation (AT/AF) expressed as a percentage of total recording time.
Key Inclusion Criteria:
History of PAF documented within the prior 12 months
Key Exclusion Criteria:
Disease - specific:
Concomitant medications/food
Need for concomitant treatment during the trial, with drugs or products that are strong inhibitors of cytochrome P450 3A (), or inducers of CYP3A
Laboratory tests:
Others:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranolazine placebo plus dronedarone placebo for 12 weeks.
Drug: Ranolazine placebo · Drug: Dronedarone placebo
Ranolazine 750 mg plus dronedarone placebo for 12 weeks.
Drug: Ranolazine · Drug: Dronedarone placebo
Ranolazine placebo plus dronedarone 225 mg for 12 weeks.
Drug: Dronedarone · Drug: Ranolazine placebo
Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.
Drug: Ranolazine · Drug: Dronedarone
Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.
Drug: Ranolazine · Drug: Dronedarone
Tablets administered orally twice daily.
Also known as: Ranexa®
Capsule administered orally twice daily
Tablets administered orally twice daily.
Capsules administered orally twice daily
Atrial Fibrillation Burden (AFB) at Baseline
AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated.
Time frame: Baseline
Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12
AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. Geometric mean is the mean of log-transformed AFB exponentiated.
Time frame: Baseline; Week 12
Absolute Change From Baseline in AFB by Week 12
AFB is defined as the total time a participant is in AT/AF expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment.
Time frame: Baseline; Week 12
Percentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB
AFB was defined as the total time a participant was in AT/AF expressed as a percentage of total recording time.
Time frame: Week 12
Participants were enrolled at study sites in Germany, Israel, Italy, Netherlands, Poland, and the United States. The first participant was screened on 24 January 2012. The last study visit occurred on 10 March 2014.
| Milestone | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg |
|---|---|---|---|---|---|
| Started | 26 | 27 | 26 | 28 | 27 |
| Completed | 17 | 19 | 22 | 20 | 21 |
| Not completed | 9 | 8 | 4 | 8 | 6 |
| Withdrew: Adverse event | 3 | 4 | 4 | 5 | 4 |
| Withdrew: Cardioversion | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Device malfunction | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Investigator's discretion | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant non-compliance | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 0 | 1 | 1 |
| Withdrew: Randomized but never treated | 0 | 1 | 0 | 1 | 1 |
AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated.
| Percentage of total recording time | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg |
|---|---|---|---|---|---|
| Atrial Fibrillation Burden (AFB) at Baseline | 12.7 ± 2.21 | 10.8 ± 2.70 | 11.6 ± 2.47 | 11.7 ± 2.40 | 11.7 ± 2.04 |
AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. Geometric mean is the mean of log-transformed AFB exponentiated.
| percent change | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12 | -5.9 ± 18.00 | -23.0 ± 21.17 | 3.5 ± 15.68 | -59.1 ± 10.47 | -45.5 ± 10.73 |
AFB is defined as the total time a participant is in AT/AF expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment.
| percentage of total recording time | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg |
|---|---|---|---|---|---|
| Baseline | 16.8 ± 3.66 | 17.3 ± 3.74 | 19.1 ± 4.14 | 16.8 ± 3.11 | 16.7 ± 3.52 |
| Absolute Change From Baseline in AFB by Week 12 | 4.6 ± 3.19 | -3.1 ± 2.17 | 5.6 ± 2.65 | -4.7 ± 3.24 | -3.9 ± 3.11 |
AFB was defined as the total time a participant was in AT/AF expressed as a percentage of total recording time.
| percentage of participants | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg |
|---|---|---|---|---|---|
| ≥ 30% Reduction From Baseline AFB | 22.2 | 50.0 | 21.7 | 45.0 | 54.5 |
| ≥ 50% Reduction From Baseline AFB | 16.7 | 22.2 | 13.0 | 45.0 | 54.5 |
| ≥ 70% Reduction From Baseline AFB | 11.1 | 16.7 | 8.7 | 45.0 | 27.3 |
Collected over Adverse Events: First dose date up to the last dose date (maximum 102 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/26 (0%) | 1/26 (3.8%) | 9/26 (34.6%) |
| Ranolazine 750 mg | 0/26 (0%) | 7/26 (26.9%) | 15/26 (57.7%) |
| Dronedarone 225 mg | 0/26 (0%) | 2/26 (7.7%) | 14/26 (53.8%) |
| Ranolazine 750 mg + Dronedarone 225 mg | 0/27 (0%) | 5/27 (18.5%) | 12/27 (44.4%) |
| Ranolazine 750 mg + Dronedarone 150 mg | 0/26 (0%) | 1/26 (3.8%) | 14/26 (53.8%) |
| Event | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/26 | 3/26 | 1/26 | 0/27 | 1/26 |
| Atrial flutterCardiac disorders | 1/26 | 0/26 | 0/26 | 0/27 | 0/26 |
| Cardiac failure congestiveCardiac disorders | 0/26 | 0/26 | 1/26 | 0/27 | 0/26 |
| TachyarrhythmiaCardiac disorders | 0/26 | 0/26 | 1/26 | 0/27 | 0/26 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/26 | 1/26 | 0/26 | 0/27 | 0/26 |
| International normalised ratio increasedInvestigations | 0/26 | 1/26 | 0/26 | 1/27 | 0/26 |
| PresyncopeNervous system disorders | 0/26 | 1/26 | 0/26 | 0/27 | 0/26 |
| HypertensionVascular disorders | 0/26 | 1/26 | 0/26 | 0/27 | 0/26 |
| VertigoEar and labyrinth disorders | 0/26 | 0/26 | 0/26 | 1/27 | 0/26 |
| Chest painGeneral disorders | 0/26 | 0/26 | 0/26 | 1/27 | 0/26 |
| Event | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 2/26 | 0/26 | 4/26 | 1/27 | 2/26 |
| ConstipationGastrointestinal disorders | 0/26 | 1/26 | 1/26 | 1/27 | 4/26 |
| VertigoEar and labyrinth disorders | 0/26 | 3/26 | 0/26 | 0/27 | 1/26 |
| Abdominal painGastrointestinal disorders | 0/26 | 0/26 | 3/26 | 2/27 | 0/26 |
| NauseaGastrointestinal disorders | 0/26 | 3/26 | 1/26 | 2/27 | 1/26 |
| FatigueGeneral disorders | 0/26 | 3/26 | 0/26 | 2/27 | 1/26 |
| Oedema peripheralGeneral disorders | 0/26 | 0/26 | 3/26 | 2/27 | 0/26 |
| Urinary tract infectionInfections and infestations | 3/26 | 1/26 | 2/26 | 0/27 | 0/26 |
| DizzinessNervous system disorders | 1/26 | 3/26 | 2/26 | 0/27 | 2/26 |
| HypotensionVascular disorders | 0/26 | 0/26 | 0/26 | 3/27 | 1/26 |
The Safety Analysis Set included participants who received ≥ 1 dose of study drug (ranolazine/placebo tablets or dronedarone/placebo capsules).
| Age, Continuous(years) | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 72 ± 8.4 | 70 ± 10.8 | 75 ± 7.8 | 71 ± 7.1 | 73 ± 9.4 | 72 ± 8.8 |
| Sex: Female, Male(Participants) | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg | Total |
|---|---|---|---|---|---|---|
| Female | 13 | 16 | 16 | 12 | 11 | 68 |
| Male | 13 | 10 | 10 | 15 | 15 | 63 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 3 | 1 | 6 |
| Not Hispanic or Latino | 22 | 25 | 26 | 24 | 25 | 122 |
| Unknown or Not Reported | 2 | 1 | 0 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 26 | 26 | 26 | 27 | 25 | 130 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | Ranolazine 750 mg | Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 225 mg | Ranolazine 750 mg + Dronedarone 150 mg | Total |
|---|---|---|---|---|---|---|
| Germany | 5 | 4 | 8 | 4 | 2 | 23 |
| Israel | 5 | 6 | 1 | 6 | 6 | 24 |
| Italy | 0 | 0 | 0 | 1 | 0 | 1 |
| Netherlands | 0 | 0 | 0 | 0 | 1 | 1 |
| Poland | 10 | 12 | 11 | 11 | 15 | 59 |
| United States | 6 | 4 | 6 | 5 | 2 | 23 |
Ran from Jan 2012 to primary completion in Mar 2014, 25 months.
Results were first posted in Nov 2020, 6 years 7 months after primary completion. A results delay was requested in Aug 2014.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ranolazine · Dronedarone